ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e)

On February 24, 2017, we increased the maximum bonus payable to Albert W. Brzeczko, Vice President Technical Affairs of our subsidiary Acura Pharmaceutical Technologies, Inc. from 35% to 50% of base salary under our non-equity bonus incentive plan. Dr. Brzeczko’s base salary is currently $291,000 per year.

About ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR)

Acura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company’s Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company’s Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company’s Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.

ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR) Recent Trading Information

ACURA PHARMACEUTICALS, INC. (NASDAQ:ACUR) closed its last trading session down -0.095 at 0.505 with 513,075 shares trading hands.